NCT01570608

Lucentis KAV Study

Comparison of Ranibizumab (Lucentis) Monotherapy Versus Combination of Ranibizumab (Lucentis) With Photodynamic Therapy (Verteporfin) in Patients With Subfoveal Choroidal Neovascularisation Due to Age-Related Macular Degeneration - a Pilot Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

Ranibizumab has been proven to be effective in large multicentre studies. However, the injections have to be repeated monthly. A combined therapy with the established photodynamic therapy might even be more effective, less intravitreal injections might be necessary due to a synergistic effect. The study will be conducted to explore whether intravitreal ranibizumab in monotherapy or in combination with verteporfin photodynamic therapy under a new time regime is an effective, safe and convenient treatment for patients with subfoveal Choroidal Neovascularisation (CNV) secondary to Age-Related Macular Degeneration (AMD).

Conditions

• Age Related Macular Degeneration

Interventions

Type	Name	Description
DRUG	Ranibizumab	intravitreal injection 3 monthly injections thereafter as needed
DRUG	Verteporfin	Verteporfin photodynamic therapy standard fluence

Timeline

• Start date: 2007-03-01
• Primary completion: 2011-08-01
• Completion: 2011-08-01
• First posted: 2012-04-04
• Last updated: 2012-04-04

Locations

3 sites across 1 country: Austria